Numinus Wellness (TSE:NUMI) has released an update.
Numinus Wellness Inc., a forerunner in mental health care, has responded to the FDA’s advisory committee’s vote against recommending approval of MDMA for PTSD treatment, despite some positive trial results. The company remains hopeful for future approval and is actively involved with developing other potential psychedelic treatments, currently at various stages of clinical trials. Meanwhile, Numinus continues to offer other treatments like Spravato and ketamine in its clinics and is committed to achieving profitability independent of new therapy commercialization.
For further insights into TSE:NUMI stock, check out TipRanks’ Stock Analysis page.
